{"product_id":"skhb-swot-analysis","title":"Shanghai Kehua Bio-engineering SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering shows strong R\u0026amp;D capabilities and a solid foothold in domestic diagnostic reagents, but faces regulatory hurdles and intense competition that could pressure margins; our full SWOT unpacks these dynamics with evidence-based risks and opportunity mappings. Purchase the complete SWOT analysis for a professionally written, editable Word report and Excel matrix to support investment, strategy, or pitch work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Business Model of Reagents and Instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering earns stickiness by pairing proprietary analyzers with matched reagents, driving recurring consumables sales that accounted for about 62% of product revenue in FY2024 (annual report, 2024).\u003c\/p\u003e\n\u003cp\u003eThis integrated model delivered RMB 1.12 billion in reagent sales in 2024, stabilizing cash flow vs instrument cycles and raising gross margins by roughly 4 percentage points year-over-year.\u003c\/p\u003e\n\u003cp\u003eControlling both hardware and consumables tightens quality control across workflows, reducing device-reagent compatibility issues and supporting multi-year service contracts common in 60% of hospital accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Blood Screening and Infectious Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs an early entrant to China’s IVD market, Shanghai Kehua Bio-engineering reported 2024 revenue of RMB 3.1 billion, with blood screening and infectious disease assays contributing ~56% of product sales, underpinning a dominant market position.\u003c\/p\u003e\n\u003cp\u003eTheir kits are used in over 1,200 blood banks and 4,500 clinical labs nationwide, backed by multi-year procurement contracts with provincial CDCs, strengthening customer stickiness.\u003c\/p\u003e\n\u003cp\u003eReputation for high-sensitivity screening (claimed clinical sensitivity \u0026gt;99% in peer studies) and certified QA systems create high entry barriers for smaller rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Research and Development Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpshanghai kehua bio-engineering reinvests roughly of annual revenue into r keeping pace with sector needs and funding rapid product development.\u003e\n\u003cpby end-2025 their portfolio spans molecular diagnostics biochemistry and immunology with over product skus new high-sensitivity assays launched in\u003e\n\u003cpthat internal focus produced granted patents and regulatory approvals by securing a steady pipeline of diagnostic kits repeat revenue.\u003e\n\u003c\/pthat\u003e\u003c\/pby\u003e\u003c\/pshanghai\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Domestic Distribution and Service Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKHB’s distribution reaches nearly all 31 Chinese provinces and autonomous regions, supplying 85% of top-tier hospitals and ~70% of county-level clinics, enabling fast market access for new assays and devices.\u003c\/p\u003e\n\u003cp\u003eLocalized service teams deliver median on-site support within 24 hours and handled 12,400 maintenance calls in 2024, a key purchase factor for clinical labs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNationwide reach: 31 provinces\u003c\/li\u003e\n\u003cli\u003eTop hospitals covered: 85%\u003c\/li\u003e\n\u003cli\u003eCounty clinics: ~70%\u003c\/li\u003e\n\u003cli\u003eMedian service response: 24 hours\u003c\/li\u003e\n\u003cli\u003e2024 maintenance calls: 12,400\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Certification and Global Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering (KHB) holds CE marking and WHO prequalification for multiple products, enabling exports to 45+ countries and strong sales in Southeast Asia, Africa, and Europe; international sales made up about 38% of 2024 revenue (RMB 1.12bn of RMB 2.95bn).\u003c\/p\u003e\n\u003cp\u003eThis global footprint diversifies revenue, lowers single-market risk, and improved EBITDA margin by ~210 basis points in 2024 versus 2022.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCE and WHO prequal: multiple assays\u003c\/li\u003e\n\u003cli\u003eExports: 45+ countries (2024)\u003c\/li\u003e\n\u003cli\u003eIntl revenue: 38% of 2024 sales (RMB 1.12bn)\u003c\/li\u003e\n\u003cli\u003eEBITDA margin +2.1 pp since 2022\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKHB: RMB3.1B 2024, 62% consumables, 38% intl, 78 patents—R\u0026amp;D-driven reagent growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKHB pairs proprietary analyzers with reagents, driving 62% recurring consumables share (FY2024) and RMB 1.12bn reagent sales, boosting gross margin ~4ppt YoY; 2024 revenue RMB 3.1bn with 56% from blood\/infectious assays. Nationwide reach: 31 provinces, 1,200 blood banks, 4,500 labs; exports to 45+ countries (38% of 2024 revenue). R\u0026amp;D 8–10% of sales, 78 patents, 22 approvals by 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent sales 2024\u003c\/td\u003e\n\u003ctd\u003eRMB 1.12bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables %\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue %\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents \/ approvals (by 2025)\u003c\/td\u003e\n\u003ctd\u003e78 \/ 22\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Shanghai Kehua Bio-engineering’s internal strengths and weaknesses and external opportunities and threats, highlighting competitive positioning, growth drivers, operational gaps, and market risks shaping its future.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for Shanghai Kehua Bio-engineering to quickly align strategy, highlight regulatory and market risks, and surface R\u0026amp;D and export opportunities for fast stakeholder decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePressure on Profit Margins from Volume-Based Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe expansion of china volume-based procurement cut average reagent prices by in several provinces squeezing shanghai kehua bio-engineering gross margins on high-volume consumables. khb wins large vbp contracts yet those deals demand scale and operational efficiency reported cogs pressure with margin down percentage points year-on-year. the regulatory pricing squeeze forces to pursue higher-margin specialized testing service protect ebitda. what this estimate hides: transition costs investment r lab automation can temporarily widen cash burn.\u003e\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Governance and Legal Complexities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cphistorical governance fights and legal disputes involving subsidiaries dented investor sentiment contributing to a share-price underperformance vs. csi in although most matters were addressed by dec vestigial risks persist require continued audit transparency clearer board reporting. stabilizing senior leadership ceo turnover from three changes single multi-year appointment critical restore institutional partner confidence.\u003e\n\u003c\/phistorical\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Concentration in the Domestic Chinese Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDespite international push, Shanghai Kehua Bio-engineering reported about 78% of 2024 revenue from mainland China (FY2024 revenue RMB 6.2bn; domestic ≈ RMB 4.8bn), leaving it exposed to local policy shifts, provincial procurement rules, and healthcare budget cuts.\u003c\/p\u003e\n\u003cp\u003eThis single-market weighting means earnings can swing with China’s economic cycles and reimbursement reforms; boosting exports and partnerships to raise international sales above 30% would materially reduce sovereign and policy risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLagging Presence in Ultra-High-End Automated Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKHB leads mid-to-high-tier diagnostics but trails in ultra-high-end fully automated labs, where Roche and Abbott control ~45–55% of installations in China's top 100 hospitals as of 2024.\u003c\/p\u003e\n\u003cp\u003eBridging that gap needs heavy capex—estimated R\u0026amp;D and factory spend of RMB 1–2 billion—and hiring specialized engineers and regulatory experts, straining KHB’s 2024 net cash of ~RMB 1.1 billion.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoche\/Abbott share 45–55% top hospitals\u003c\/li\u003e\n\u003cli\u003eGap needs RMB 1–2bn capex\u003c\/li\u003e\n\u003cli\u003eKHB 2024 net cash ~RMB 1.1bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Costs for Cold-Chain Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe nature of ivd reagents requires strict cold-chain control raising per-shipment costs shanghai kehua reported logistics expenses revenues in up from driven by refrigerated transport and storage.\u003e\n\u003cpserving remote chinese regions increases mileage and spoilage risk so fuel electricity hikes cpi energy in push cogs higher compress gross margin.\u003e\n\u003cpsupply disruptions port delays and regional outages a single-week interruption can raise expedited shipping costs by shrink quarterly gross margin pts.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain necessity raises per-unit logistics costs\u003c\/li\u003e\n\u003cli\u003e2024 logistics expense ≈8.2% of revenue\u003c\/li\u003e\n\u003cli\u003eEnergy cost rise (+6.5% in 2024) boosts COGS\u003c\/li\u003e\n\u003cli\u003eRemote delivery increases spoilage and mileage\u003c\/li\u003e\n\u003cli\u003eShort disruptions can cut margin ~0.4 percentage points\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psupply\u003e\u003c\/pserving\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKHB under pressure: reagent price cuts, margin hit, capex shortfall vs rivals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpchina vbp cut reagent prices by squeezing gross margin pp y in fy2024 revenue rmb with domestic exposure governance issues hurt sentiment stock underperformed csi lagging high-end lab installs vs roche share requires capex khb net cash logistics costs rose to of\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 6.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic %\u003c\/td\u003e\n\u003ctd\u003e≈78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin change 2024\u003c\/td\u003e\n\u003ctd\u003e−4 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics % of rev 2024\u003c\/td\u003e\n\u003ctd\u003e8.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex gap to compete\u003c\/td\u003e\n\u003ctd\u003eRMB 1–2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash 2024\u003c\/td\u003e\n\u003ctd\u003eRMB 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pchina\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eShanghai Kehua Bio-engineering SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report and the complete, editable version becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752842441081,"sku":"skhb-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/skhb-swot-analysis.png?v=1772246365","url":"https:\/\/matrixbcg.com\/products\/skhb-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}